Aequus Pharmaceuticals Inc (AQS) - Total Liabilities

Latest as of September 2025: CA$7.09 Million CAD ≈ $5.13 Million USD

Based on the latest financial reports, Aequus Pharmaceuticals Inc (AQS) has total liabilities worth CA$7.09 Million CAD (≈ $5.13 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Aequus Pharmaceuticals Inc to assess how effectively this company generates cash.

Aequus Pharmaceuticals Inc - Total Liabilities Trend (2013–2024)

This chart illustrates how Aequus Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check Aequus Pharmaceuticals Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.

Aequus Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of Aequus Pharmaceuticals Inc ranked by their total liabilities.

Company Country Total Liabilities
Upsellon Brands Holdings Ltd
TA:CHR
Israel ILA2.01 Million
Craven House Capital PLC
LSE:CRV
UK $1.93 Million
Foncière 7 investissement Société Anonyme
PA:LEBL
France €57.45K
CML Microsystems Plc
LSE:CML
UK GBX14.82 Million
Time Out Group plc
LSE:TMO
UK GBX110.88 Million
Gelion PLC
LSE:GELN
UK GBX1.54 Million
Time Finance PLC
LSE:TIME
UK GBX170.01 Million
TCTM Kids IT Education Inc.
NASDAQ:VSA
USA $1.83 Billion

Liability Composition Analysis (2013–2024)

This chart breaks down Aequus Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Aequus Pharmaceuticals Inc worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.03 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.03 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 36.14 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Aequus Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Aequus Pharmaceuticals Inc (2013–2024)

The table below shows the annual total liabilities of Aequus Pharmaceuticals Inc from 2013 to 2024.

Year Total Liabilities Change
2024-12-31 CA$7.26 Million
≈ $5.25 Million
+34.85%
2023-12-31 CA$5.38 Million
≈ $3.89 Million
+75.16%
2022-12-31 CA$3.07 Million
≈ $2.22 Million
+20.03%
2021-12-31 CA$2.56 Million
≈ $1.85 Million
-0.07%
2020-12-31 CA$2.56 Million
≈ $1.85 Million
+0.43%
2019-12-31 CA$2.55 Million
≈ $1.84 Million
+709.71%
2018-12-31 CA$314.90K
≈ $227.79K
-14.16%
2017-12-31 CA$366.84K
≈ $265.36K
-50.72%
2016-12-31 CA$744.41K
≈ $538.50K
-34.99%
2015-12-31 CA$1.15 Million
≈ $828.33K
+53.80%
2014-12-31 CA$744.51K
≈ $538.56K
+1212.23%
2013-12-31 CA$56.74K
≈ $41.04K
--

About Aequus Pharmaceuticals Inc

V:AQS Canada Drug Manufacturers - Specialty & Generic
Market Cap
$479.73K
CA$663.17K CAD
Market Cap Rank
#30557 Global
#1646 in Canada
Share Price
CA$0.01
Change (1 day)
+0.00%
52-Week Range
CA$0.01 - CA$0.01
All Time High
CA$0.69
About

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceu… Read more